FindTrial
Sign In

PF-08634404

BIOLOGICAL12 trials

Sponsors

Pfizer Inc., Pfizer

Conditions

Advanced Hepatocellular CarcinomaAdvanced Non-Small Cell Lung CancerAdvanced Renal Cell CarcinomaAdvanced or Metastatic Renal Cell CarcinomaAdvanced/Metastatic Non-Small Cell Lung CancerAdvanced/Metastatic Urothelial CancerCarcinomaCarcinoma, Hepatocellular

Phase 1

A Study to Learn About the Medicine Called PF-08634404 Dosed Alone and in Combination With Other Anticancer Therapies in Adults With Locally Advanced or Metastatic Renal Cell Cancer
RecruitingNCT07227415
PfizerAdvanced or Metastatic Renal Cell Carcinoma, Advanced Renal Cell Carcinoma, Carcinoma, Renal Cell +10
Start: 2026-02-10End: 2028-11-01Target: 224Updated: 2026-03-02
A Study to Learn About Study Medicine Called PF-08634404 as a Single Treatment and Combination Treatment in Adult Participants With a Liver Cancer Called Hepatocellular Carcinoma, That is Too Advanced to be Removed by Surgery and May Have Spread to Other Parts of the Body.
RecruitingNCT07227012
PfizerAdvanced Hepatocellular Carcinoma, Carcinoma, Hepatocellular, Hepatocellular Cancer +4
Start: 2025-12-01End: 2028-10-17Target: 138Updated: 2025-12-18
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Different Anticancer Agents in Advanced Cancers
RecruitingNCT07227298
PfizerAdvanced/Metastatic Non-Small Cell Lung Cancer, Carcinoma, Non-Small Cell Lung, Non-Small Cell Lung Cancer
Start: 2026-01-30End: 2033-08-23Target: 162Updated: 2026-03-02
A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
Not yet recruitingNCT07421700
PfizerAdvanced/Metastatic Urothelial Cancer, Urothelial Cancer, Urothelial Carcinoma
Start: 2026-02-27End: 2028-09-05Target: 132Updated: 2026-02-19

Phase 2

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Extensive-Stage Small Cell Lung Cancer
RecruitingNCT07226999
PfizerSmall Cell Lung Cancer (SCLC)
Start: 2025-12-09End: 2034-03-11Target: 550Updated: 2026-01-12
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Gastroesophageal Cancer
Not yet recruitingNCT07392892
PfizerEsophageal Adenocarcinoma, Gastroesophageal Junction Cancer, Metastatic Gastric Cancer +1
Start: 2026-03-02End: 2032-07-21Target: 840Updated: 2026-02-06
Symbiotic-Lung-14: A Study to Learn About the Study Medicine Called PF08634404 in Combination With Chemotherapy in Adult Participants With Transformed Small Cell Lung Cancer
Not yet recruitingNCT07476287
PfizerCarcinoma, Small Cell Lung, Lung Neoplasms, Small Cell Cancer Of The Lung +3
Start: 2026-05-15End: 2031-03-19Target: 40Updated: 2026-03-17
Symbiotic-Lung-10: A Study to Learn About PF-08634404 Alone or in Combination in Early-stage or Locally Advanced NSCLC
Not yet recruitingNCT07489066
PfizerCarcinoma, Carcinoma, Non-Small-Cell Lung (NSCLC), Lung Cancer (NSCLC) +6
Start: 2026-04-01End: 2031-08-05Target: 120Updated: 2026-03-23

Phase 3

A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Metastatic Colorectal Cancer
RecruitingNCT07222800
PfizerColonic Diseases, Colorectal Neoplasms, Digestive System Diseases +7
Start: 2025-12-11End: 2031-08-01Target: 800Updated: 2026-01-30
A Study to Learn About the Study Medicine Called PF-08634404 in Combination With Chemotherapy in Adult Participants With Locally Advanced or Metastatic Non-Small Cell Lung Cancer
RecruitingNCT07222566
PfizerAdvanced Non-Small Cell Lung Cancer, Carcinoma, Non-Small-Cell Lung, Carcinoma, Non-Small-Cell Lung (NSCLC) +3
Start: 2026-01-06End: 2032-08-26Target: 1410Updated: 2026-01-23
C6461003 - AN INTERVENTIONAL, PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS BEVACIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN TREATMENT-NAÏVE PARTICIPANTS WITH METASTATIC COLORECTAL CANCER
Not yet recruitingCTIS2025-523521-18-00
Pfizer Inc.Metastatic Colorectal Cancer
Target: 20Updated: 2026-03-23
AN INTERVENTIONAL PHASE 3, DOUBLE-BLIND, RANDOMIZED STUDY TO EVALUATE EFFICACY AND SAFETY OF PF-08634404 IN COMBINATION WITH CHEMOTHERAPY VERSUS PEMBROLIZUMAB IN COMBINATION WITH CHEMOTHERAPY IN ADULT PARTICIPANTS WITH LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Not yet recruitingCTIS2025-523461-17-01
Pfizer Inc.LOCALLY ADVANCED OR METASTATIC NON-SMALL CELL LUNG CANCER
Target: 203Updated: 2026-03-25